A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Pubertal development and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy: a retrospective study




TekijätTräskilä Emilia, Holopainen Elina, Mäyränpää Mikko I., Toppari Jorma, Mäkitie Outi, Laakso Saila

KustantajaBioScientifica Ltd.

Julkaisuvuosi2023

JournalEuropean Journal of Endocrinology

Tietokannassa oleva lehden nimiEuropean Journal of Endocrinology

Vuosikerta188

Numero4

eISSN1479-683X

DOIhttps://doi.org/10.1093/ejendo/lvad034

Verkko-osoitehttps://doi.org/10.1093/ejendo/lvad034

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179813667


Tiivistelmä

The aim of this study was to describe the course of puberty and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a Finnish APECED cohort followed up between 1970 and 2020. Anthropometry, testicular volumes and FSH, LH, and testosterone concentrations were analyzed retrospectively. Forty-three males were followed up until the median age of 42.5 years (range, 16.2-74.8). All subjects fulfilled the clinical criteria for APECED. The median age at the onset of spontaneous puberty was 13.3 years (10.8-14.8). Testosterone medication was used to promote pubertal development from the median age of 14.9 years (13.5-15.7), for 0.7-3.3 years in 8 patients. The median adult height was 173.0 cm and differed from the mid-parental target height on average −1.3 SDS (P < .001). Hypogonadism was treated in 6 patients (14%). Azoospermia was found in 3 patients. Further studies are required to explore the role of the autoimmune regulator in sperm production and testicular insufficiency.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-03 at 21:53